Clinical trials
Glioblastoma, IDH-wildtype clinical trials
Below are recruiting glioblastoma, idh-wildtype clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06850766Recruiting
Timing of chemotherapy (morning vs evening) for glioblastoma
This trial tests whether taking the chemotherapy drug temozolomide in the morning or in the evening works better and causes fewer side effects for people with a type of brain cancer called glioblastoma.
London, OntarioAges 18 years+ - NCT05929495RecruitingPhase 2
Metformin added to standard treatment for newly diagnosed glioblastoma
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
MilanAges 18 years+ - NCT06419946RecruitingPhase 3
Lomustine study for MGMT methylated glioblastoma
This trial tests adding lomustine chemotherapy to standard treatment for people with a specific type of glioblastoma that has a methylated MGMT gene. It aims to see if this combination helps control the tumor better and improves survival.
GrazAges 18–70 - NCT06410248RecruitingPhase 1
Triapine with temozolomide for recurrent glioblastoma
This trial is testing a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06319027RecruitingPhase 2
Can brain scans help predict glioblastoma progression?
This trial is testing whether certain details on brain scans can help doctors better predict how brain cancer (glioblastoma) will progress. You may be eligible if you are newly diagnosed with this type of cancer and plan to receive standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT04945148RecruitingPhase 2
Metformin plus radiation and chemo for glioblastoma subtype
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
Suresnes, Hauts de SeineAges 18 years+ - NCT05879250RecruitingPhase 2
WP1066 plus radiation for newly diagnosed glioblastoma
This trial tests whether the study drug WP1066 combined with radiation can better control newly diagnosed glioblastoma, a fast-growing brain tumor. It also aims to check safety and how well tumors respond by using brain scans.
Chicago, IllinoisAges 18 years+ - NCT05789394RecruitingPhase 1
Stem cell treatment for recurrent brain tumor surgery
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
Jacksonville, FloridaAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Phoenix, ArizonaAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT06552260RecruitingEarly Phase 1
Troriluzole before surgery for recurrent glioblastoma
This trial tests whether an investigational drug called troriluzole can help people with recurrent glioblastoma (a type of brain tumor). You would take the drug for a short time before your planned surgery, so researchers can study how the drug affects your tumor tissue. The goal is to see if it might slow tumor growth.
Boston, MassachusettsAges 18 years+ - NCT06623565Recruiting
Advanced imaging for extensive brain tumor removal
This trial uses advanced imaging to help surgeons remove as much of a malignant brain tumor as safely possible. It may be a good fit if you have a new diagnosis of glioblastoma or a certain astrocytoma and are healthy enough for surgery.
Amsterdam, North HollandAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma, idh-wildtype?
- Yes. Clin2 currently lists 40 recruiting glioblastoma, idh-wildtype studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma, idh-wildtype trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma, idh-wildtype trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.